Citations

Clear

1152 citation(s) found for "Todd, A".

Body Mass Index ≥45 Is Associated With an Increased Risk of Health Care Utilization and Long-term Complications After Total Ankle Arthroplasty
Holle, Alejandro M, Alhankawi, Ahmad R. , Parmar, Romir , Kile, Todd A. , Holle, Alejandro M. , Holle, Alejandro , Tummala, Sailesh V , Tummala, Sailesh V.

Mayo Clinic

Foot & Ankle Orthopaedics | May 25, 2026 | Volume: 11 | Issue: 2 | Pages: No page available

10.1177/24730114261448846 Get It

Background: The impact of obesity on outcomes following total ankle arthroplasty (TAA) remains unclear, with existing literature reporting mixed results. Although some studies have identified obesity as a risk factor for perioperative complications and poor clinical outcomes, others have found no significant association. Thus, the purpose of this study was to evaluate the association between obesity, across a range of body mass index (BMI) classifications, and postoperative complications after TAA. Methods: Patients undergoing primary TAA were identified from a large national insurance database. Individuals with a BMI ≥30 were identified and matched 1:1 to nonobese controls using propensity score matching based on demographics and comorbidities. Obese patients were further stratified into BMI categories: 30-34.9, 35-39.9, 40-44.9, and ≥45. Ninety-day complications and 2-, 5-, and 10-year surgery-specific outcomes were assessed. Odds ratios (ORs) with 95% CIs and Kaplan-Meier survival analyses were used to evaluate complication risks. Results: After matching, 3364 patients were included in each cohort. No significant differences in 90-day complication rates were observed for patients with BMI 30-44.9 compared with controls. Patients with BMI ≥45 had increased risk of surgical site infection (OR 2.21, 95% CI 1.29-3.79, P = .003), emergency department visits (OR 1.43, 95% CI 1.04-1.96, P = .025), and readmissions (OR 2.31, 95% CI 1.47-3.63, P < .001). The pooled 90-day complication rate was significantly higher in this group as well (12.9% vs 7.6%, OR 1.77, 95% CI 1.26-2.48, P < .001). At 10-year follow-up, Kaplan-Meier analysis demonstrated that patients with a BMI ≥45 had a higher risk of periprosthetic joint infection (PJI compared with controls (hazard ratio 1.75, 95% CI 1.07-2.85, P = .03). Patients with BMI 30-34.9 had a significantly lower risk of aseptic loosening at both 5 years (OR 0.68, 95% CI 0.49-0.94, P = .019) and 10 years (OR 0.65, 95% CI 0.48-0.88, P = .005). Conclusion: BMI ≥45 was associated with higher all-cause health care utilization, including emergency department visits and hospital readmissions, as well as higher long-term risk of PJI following TAA. Level of Evidence: Level III, retrospective cohort study.
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Banerjee, Rahul , Cheung, Matthew C. , Derman, Benjamin, Messersmith, Hans , Bhella, Sita, Chmielewski, Cynthia, Ebraheem, Mohammad, Kennedy, C. Todd , Kumar, Shaji , Langerak, Alan, Mian, Hira , Seth, Rahul, Subramanian, Latha, Wildes, Tanya M., Zanwar, Saurabh , Zhuo, Ying, Derman, Benjamin A , Al Hadidi, Samer , Ebraheem, Mohammad S , Kennedy, C Todd , Kumar, Shaji K , Lipe, Brea , Mian, Hira , Riva, Eloisa , Usmani, Saad , Wildes, Tanya , Zanwar, Saurabh S , Hicks, Lisa K. , Messersmith, Hans , Banerjee, Rahul , Derman, Benjamin A. , Chmielewski, Cynthia, Langerak, Alan, Seth, Rahul, Usmani, Saad Z. , Wildes, Tanya M.

Mayo Clinic

Journal of Clinical Oncology | May 20, 2026 | Volume: 44 | Issue: 22 | Pages: No page available

10.1200/jco-26-01139 | PMID 42160714 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found on the ASCO Publications website .
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas
Gottesdiener, Lee , Li, Yixuan, Greenwood‐Quaintance, Kerryl E. , Komarow, Lauren, Arias, César A. , Cober, Eric, Herc, Erica , Kaye, Keith S., Huskins, W. Charles, Figueroa, Jairo, Vilchez, Samuel, Leroi, Marcel, Rioseco, María L., Munita, Jose M., Reyes, Jinnethe , Kreiswirth, Barry N. , Hill, Carol, Baum, Keri, Chambers, Henry F., Fowler, Vance G. , Doi, Yohei, Satlin, Michael J., Group, on behalf of the Antibacterial Resistance Leadership, Munita, José M. , Fries, Bettina C , Reyes, Jinnethe , Chen, Liang , Kreiswirth, Barry N , Villegas, Maria Virginia , Paterson, David L. , Bonomo, Robert A , Fowler, Vance G. , Patel, Robin , van Duin, David , Satlin, Michael J , Evans, Scott R , Munita, Jose M , Komarow, Lauren , Arias, César A. , Cober, Eric , Kaye, Keith S. , Huskins, W. Charles , Fries, Bettina C. , Leroi, Marcel , McCarty, Todd P , Rioseco, María Luisa, Stryjewski, Martín E. , Hill, Carol , Baum, Keri, Villegas, María Virginia , Bonomo, Robert A. , Chambers, Henry F. , Patel, Robin , Doi, Yohei , Satlin, Michael J.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 15, 2026 | Volume: 70 | Issue: 6 | Pages: No page available

10.1128/aac.00388-25 | PMID 42138639 Get It

ABSTRACT Novel β-lactam/β-lactamase inhibitors (βL/βLIs) are important therapies for carbapenem-resistant Pseudomonas aeruginosa (CRPA). However, the global extent of resistance to these agents and the impact of resistance on patient outcomes are unclear. We therefore evaluated patients with CRPA isolates at 35 hospitals (nine countries) from December 2018 to November 2019. Antimicrobial susceptibility testing was performed at a central laboratory by agar dilution for ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) and by broth microdilution for imipenem-relebactam (I/R). Characteristics and outcomes, including desirability of outcome rankings (DOOR), were compared between patients infected with isolates not susceptible vs susceptible to each agent. Of 800 CRPA isolates, susceptibility to C/T, CZA, and I/R was 69%, 67%, and 33%, respectively. USA isolates ( n = 526) were more frequently susceptible to these agents than isolates from other countries ( n = 274; C/T: 83% vs 42%; CZA: 77% vs 47%; I/R: 37% vs 23%; P < 0.001 for each comparison) and isolates with carbapenemases ( n = 157) were less frequently susceptible than isolates without carbapenemases ( n = 643; C/T: 7% vs 84%; CZA: 24% vs 77%; I/R: 6% vs 39%; P < 0.001 for each comparison). Thirty-day mortality and DOOR were similar overall in patients infected with isolates not susceptible vs susceptible to each βL/βLI. However, the adjusted probability of a better DOOR outcome for a randomly selected patient with bacteremia due to a C/T-not susceptible vs -susceptible isolate was 38.2% (95% confidence interval, 25.6%–52.7%). Resistance to novel βL/βLIs, especially I/R, is common in CRPA, particularly outside the USA and in carbapenemase-producing isolates. Additional treatment options are needed for CRPA infections.
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026
Spratt, Daniel E., Srinivas, Sandy, Ahmed, Bilawal, An, Yi , Bitting, Rhonda, Chapin, Brian, Cheng, Heather H., D’Amico, Anthony Victor, Desai, Neil, Dorff, T. B., Eastham, James A., Farrington, Thomas A., Gao, Xin, Gupta, S, Karnes, R. Jeffrey, Kishan, Amar U., Kuettel, Michael, Lang, J., Lee, Daniel, Lotan, Tamara, McDonald, Andrew, Morgan, Todd M. , Pessoa, Rodrigo, ROACH, M, Robin, Tyler, Rosenfeld, Stan, Scarpato, Kristen R., Seibert, Tyler, Shabsigh, Ahmad, Szmulewitz, Russell, Tward, Jonathan, Valicenti, Richard, VanderWeele, David, Wong, J.K. , Kovách, E, Freedman-Cass, Deborah, Morgan, Todd M , Robin, Tyler P. , Spratt, Daniel E. , Adra, Nabil , Bitting, Rhonda L. , Chapin, Brian F. , Cheng, Heather H., Cho, Steve Y. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, Jeff , Gupta, Shilpa , Ippolito, Joseph E. , Kishan, Amar U. , McDonald, Andrew M. , Rais‐Bahrami, Soroush , Roach, Mack , Scarpato, Kristen R., Shabsigh, Ahmad , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D. , Valicenti, Richard K., VanderWeele, David James , Freedman-Cass, Deborah A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 14, 2026 | Volume: 24 | Issue: 5 | Pages: 140-149

10.6004/jnccn.2026.0023 | PMID 42134408 Get It

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel’s discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.
The Role of Emergency Medical Services in Addressing Opioid Use Disorder—A Position Statement and Resource Document of NAEMSP
Mercer, Mary P. , Murrell, Angela, Simpson, Nicholas, Knotts, Mary, Crowe, Remle, Weston, Benjamin W. , Cabañas, José G. , Cage, Todd M , Hickerson, Meredith, Glenn, Melody J , Mercer, Mary P , Murrell, Angela , Crowe, Remle , Cabañas, Jose G , Cage, Todd M , Hickerson, Meredith , Joiner, Anjni P , Simpson, Nicholas, Crowe, Remle P.

Mayo Clinic

Prehospital Emergency Care | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.1080/10903127.2026.2668009 | PMID 42114053 Get It

Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522
Hofherr, Mara, Davis, Andrew A. , January, Spenser E. , Raheem, Farah , Lyons, Lauren , Hsin, Jerline , Kraft, Shawna , Schepers, Allison , Taraba, Jodi L. , Blazawski, Jon , Bohnenkamp, Colleen, Hummert, Shelly, Grate, Lisa , Keisner, S. V., Hobbs, Jacob , Davis, Todd , White, Traci, Sandhu, Avneek Singh, Boulbol, Fouad, Finch, Kelsey , Fahey, Olivia , Resnick, Yonatan , Harwood, K., Armgardt, Emily, Mazewski, Douglas, Svoboda, Alison, Keegan, Aimee , Yu, Wai, Watson-Rose, Meredith, Madden, Katherine, Upton, Charlie, Mina, Lida, Owen, Emily , Clifton, Katherine , Hofherr, Mara Lacy , January, Spenser , Schepers, Allison J , Taraba, Jodi L , Keisner, Sidney V , Harwood, Kayla, Owen, Emily J , Clifton, Katherine , Raheem, Farah , Kraft, Shawna , Hummert, Shelly, Grate, Lisa , Madden, Katherine, Karikalan, Suganya Arunachalam

Mayo Clinic

JCO Oncology Practice | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-24-00819 | PMID 42085641 Get It

PURPOSE Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Early-stage, high-risk patients with TNBC are treated with chemotherapy and pembrolizumab per the KEYNOTE-522 regimen. This report examines real-world clinical effectiveness and toxicity of this regimen. METHODS This 19-site retrospective analysis included all patients who received at least one dose of the KEYNOTE-522 regimen. Safety, efficacy, and health care encounters were collected. RESULTS 675 patients from 19 sites in the United States who received chemotherapy and pembrolizumab for early-stage TNBC were included. 547 (81.0%) patients underwent surgery and 250 (54.7%) patients had a pathologic complete response (pCR). No baseline characteristics were predictive of pCR status. 224 patients (33.2%) had an adverse drug event resulting in ≥1 dose reduction of chemotherapy and were significantly more likely to have residual disease. Immune-related adverse events (irAEs) were observed in 388 (57.5%) patients and grade 3+ irAEs were observed in 176 (26.1%) patients. There was no difference in pCR status between provider's choice chemotherapy schedules. There was no difference of pCR rate between Black and White patients (55.6% v 51.6%, P = .489). White patients were significantly more likely to have any grade and grade 3+ irAEs. Older patients (age ≥65 years) had similar pCR rates compared with younger patients; however, older patients were significantly more likely to have grade 3+ irAEs. CONCLUSIONS In this multi-institutional real-world cohort, we observed a lower pCR rate, higher rates of toxicity, frequent emergency health care utilization, and the reporting of rare irAEs at higher frequency than the KEYNOTE-522 regimen. These findings have important implications for clinical management of patients with early-stage TNBC and warrant further validation with real-world data sets.
Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma
Rezaee‐Zavareh, Mohammad Saeid , Kim, Hyunseok, Luu, Michael, Ayoub, Walid, Kuo, Alexander, Trivedi, Hirsh D. , Wang, Yun, Vipani, Aarshi , Todo, Tsuyoshi , Voidonikolas, Georgios , Wisel, Steven A. , Brennan, Todd V. , Ferrone, Cristina, Kim, Irene , Kosari, Kambiz , Nissen, Nicholas, Parikh, Neehar D. , Singal, Amit G., Yang, Ju Dong , Ayoub, Walid S. , Parikh, Neehar D , Ahn, Joseph , (32846), Yun Wang, Steggerda, Justin A. , Singal, Amit G. , Yang, Ju Dong

Mayo Clinic

Hepatology Communications | April 27, 2026 | Volume: 10 | Issue: 5 | Pages: No page available

10.1097/hc9.0000000000000951 | PMID 42043868 Get It

Background: Hepatocellular carcinoma (HCC) has a poor long-term prognosis due to high recurrence and cirrhosis-related mortality, even after potentially curative treatments such as liver transplantation (LT), surgical resection, or ablation. This study aimed to identify factors associated with ≥10-year survival in HCC patients. Methods: A retrospective cohort study was conducted among HCC patients diagnosed between 2004 and 2022 using the National Cancer Database. Multivariable Cox regression was used to identify predictors of overall survival, and logistic regression was used to identify predictors of ≥10-year survival. Results: Among 249,600 HCC patients, 177,585 (71.2%) died within 5 years, 8613 (3.5%) died at 5–10 years, 54,988 (22.0%) were alive with <10 years of follow-up, and 8219 (3.3%) survived ≥10 years. LT, resection, and ablation were performed in 6.6%, 9.3%, and 11% of patients, respectively. Compared with ablation as the reference group, LT [adjusted odds ratio (aOR) 11.96, 95% confidence interval (CI): 11.27–13.29] and resection (aOR: 2.83, 95% CI: 2.57–3.08) increased the odds of ≥10-year survival, while non-curative treatments reduced the odds compared with ablation (aOR: 0.50, 95% CI: 0.47–0.55). Cox regression results were consistent with the logistic model, confirming the association. Decision tree analysis confirmed LT as the dominant determinant of long-term survival. Black individuals were associated with lower odds of ≥10-year survival (aOR: 0.88, 95% CI: 0.820–0.96) and decreased likelihood of receiving LT (aOR: 0.73, 95% CI: 0.55–0.96). Conclusions: LT offers the best chance of ≥10-year survival in HCC. Ensuring equitable access is essential, especially for Black patients who have lower transplant rates and worse outcomes.
The Importance of Plastic Surgery in Multidisciplinary Teams: A Systematic Review and Meta-analysis of Comparative Studies
Elemosho, Abdulaziz , Kardan, Ramiz, Reece, Edward M., GORDON, C, Heniford, B. Todd, Janis, Jeffrey E., Janis, Jeffrey E. , Souza, Jason M. , Heniford, B. Todd

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 21, 2026 | Volume: 14 | Issue: 4 | Pages: e7631

10.1097/gox.0000000000007631 | PMID 42021977 Get It

Background: Multidisciplinary team (MDT) care facilitates coordinated expertise that leads to improved patient safety and outcomes. Yet, no prior study has quantified reported benefits from plastic surgery–inclusive MDTs across several procedures. We thereby hypothesized that plastic surgery–inclusive MDTs would lead to better surgical outcomes following cranioplasty, spine surgery, abdominoperineal resection, abdominal wall reconstruction, and extremity reconstruction, compared with the primary specialties acting alone. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines, we searched PubMed, Embase, Scopus, and Web of Science for comparative studies comparing outcomes of care provided by plastic surgery–inclusive MDT and non–plastic surgery–inclusive MDT. Results: Thirty studies with a total of 9614 patients were included. Plastic surgery–inclusive MDT care was associated with reduced odds of wound complications in abdominoperineal resection (odds ratio [OR] = 0.65; 95% confidence interval [CI], 0.47–0.90) and spine procedures (OR = 0.57; 95% CI, 0.33–0.97). In addition, plastic surgery–inclusive MDT care for extremity reconstruction and abdominal wall reconstruction was associated with lower odds of wound complications ([OR = 0.24; 95% CI, 0.12–0.46] [OR = 0.33; 95% CI, 0.12–0.90]), reoperation ([OR = 0.13; 95% CI, 0.04–0.49] [OR = 0.26; 95% CI, 0.03–2.39]), and shorter length of stay (mean difference, −19.5 and −0.62, respectively). Conclusions: Plastic surgery–inclusive MDT care significantly reduces wound complication and reoperation rates across complex surgical procedures. These findings support the formal integration of plastic surgeons within MDTs to improve patient outcomes and surgical safety.
Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
Reducing light sensitivity during and between migraine attacks: A prospective study investigating spectral tuning of white light
Fani, Mahya, Sharp, Nina, Schwedt, Todd J. , Schwedt, Todd J , Sharp, Nina

Mayo Clinic

Cephalalgia | April 15, 2026 | Volume: 46 | Issue: 4 | Pages: No page available

10.1177/03331024261439257 | PMID 41983992 Get It

Background Photophobia is experienced by most individuals with migraine, and it is frequently the most bothersome symptom other than headache. Light is not perceived uniformly; spectral composition and intensity influence discomfort and can exacerbate symptoms. While monochromatic green light shows therapeutic potential, it appears visually unnatural and is impractical for daily use. This study aimed to determine whether spectrally tailored white light, more visually acceptable in everyday environments, reduces light sensitivity among those with migraine. Methods Twenty adults (18–44 years) with episodic migraine completed two research sessions: one during an acute migraine attack and one between migraine attacks. Participants were exposed to four spectrally distinct white light conditions (red-, green-, cyan-, and blue-enriched) in a randomized order delivered at ten intensity levels (50–590 lux). After each exposure, visual discomfort was rated on a 0–10 scale. Pupil size was measured using a pupillometer. Repeated-measures ANOVAs examined the effects of light spectrum, intensity, and migraine state on visual discomfort and pupil response. Results Migraine attack status significantly increased visual discomfort ( F (1,19) = 25.84, p < .001, η 2 = .576). White light spectrum ( F (3,57) = 12.47, p < .001, η 2 = .396) and light intensity ( F (9171) = 124.30, p < .001, η 2 = .867) were associated with intensity of visual discomfort. Post-hoc analyses indicated that visual discomfort increased with increasing light intensity, especially at higher light intensities. Among all tested spectra, green-enriched white light resulted in the least visual discomfort; blue-, red-, and cyan-enriched white light produced significantly higher discomfort (all p < .001). Pupil size varied by spectrum ( F (3,57) = 14.13, p < .001, η 2 = .426), with green-enriched white light producing the largest pupil size. Conclusion Spectral composition, light intensity, and migraine state jointly influence both subjective and physiological responses to light. Across lighting spectra, lower light intensity was consistently associated with reduced visual discomfort, indicating greater visual comfort at lower intensities. These results identify green-enriched white light at lower intensities as a visually acceptable, migraine-conscious lighting option with potential for real-world application.